CD1d–restricted invariant natural killer T-cell receptor (iNKT TCR–CD1d)

The **CD1d–restricted invariant natural killer T-cell receptor** (iNKT TCR–CD1d) is a highly conserved immune receptor complex formed when an invariant TCR (most often incorporating a specific Vα and Jα gene rearrangement) on the surface of iNKT cells recognizes glycolipid antigens presented by the monomorphic, MHC class I–like molecule CD1d on antigen-presenting cells[2][1][5][3]. This complex operates as a pattern recognition module, mediating the rapid activation of iNKT cells—lymphocytes with properties bridging innate and adaptive immunity. Upon activation, iNKT cells secrete large amounts of cytokines (e.g., IFNγ, IL-4), mediate cytotoxic activity against infected and malignant cells expressing CD1d, and orchestrate broader immune responses. The iNKT TCR–CD1d interaction is a key therapeutic target for modulating antitumor immunity, infectious diseases, and vaccine adjuvants by pharmacologic activation with glycolipid ligands (such as α-GalCer). Structural studies show the invariant TCR recognizes a composite structure of the CD1d molecule and its bound antigen, using conserved docking geometry distinct from conventional peptide–MHC TCR interactions, and with a semi-invariant TCRα chain contributing most antigen-contacting residues[1][3][5].

Other names

iNKT TCR–CD1d complexInvariant NKT TCR–CD1dType I NKT cell TCR–CD1d complexNKT T-cell receptor–CD1d

Glycolipid presentation: CD1d presents glycolipid antigens to the iNKT TCR, activating iNKT cells which then rapidly secrete cytokines and/or directly lyse target cells[2][3][1][5]. Immune modulation: iNKT activation enhances antigen-specific CD8+ T-cell responses and can be used to boost antitumor immunity[8][4]. Direct killing: iNKT cells use perforin-granzyme or Fas ligand-mediated cytotoxicity towards CD1d-expressing tumor cells[6].